ES2426194T3 - Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax - Google Patents

Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax Download PDF

Info

Publication number
ES2426194T3
ES2426194T3 ES06844159T ES06844159T ES2426194T3 ES 2426194 T3 ES2426194 T3 ES 2426194T3 ES 06844159 T ES06844159 T ES 06844159T ES 06844159 T ES06844159 T ES 06844159T ES 2426194 T3 ES2426194 T3 ES 2426194T3
Authority
ES
Spain
Prior art keywords
chimeric proteins
toxin receptor
receptor chimeric
anthrax
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06844159T
Other languages
English (en)
Inventor
Lloyd M. Yu
Keith L. Wycoff
James W. Larrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Planet Biotechnology Inc
Original Assignee
Planet Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Planet Biotechnology Inc filed Critical Planet Biotechnology Inc
Application granted granted Critical
Publication of ES2426194T3 publication Critical patent/ES2426194T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/095—Rhinovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una proteína quimérica de receptor de toxina formada por: un complejo inmunoglobulínico, que a su vez está compuesto por al menos un fragmento de cadena pesada de la inmunoglobulina G (IgG) y una proteína de morfogenia capilar 2 (CMG2) de la proteína de receptor de la toxina del carbunco, a la que le faltan los residuos de aminoácidos de SEC ID N.º: 102, unidos por enlaces covalentes con la cadena pesada de la IgG, o un fragmento de la misma.
ES06844159T 2005-08-02 2006-08-02 Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax Active ES2426194T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70482905P 2005-08-02 2005-08-02
US704829P 2005-08-02
PCT/US2006/030325 WO2007044115A2 (en) 2005-08-02 2006-08-02 Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax

Publications (1)

Publication Number Publication Date
ES2426194T3 true ES2426194T3 (es) 2013-10-21

Family

ID=37943267

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06844159T Active ES2426194T3 (es) 2005-08-02 2006-08-02 Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax

Country Status (10)

Country Link
EP (1) EP1922329B1 (es)
JP (2) JP2009502205A (es)
KR (1) KR101435420B1 (es)
CN (1) CN101277970B (es)
AU (1) AU2006299933A1 (es)
CA (1) CA2617877A1 (es)
ES (1) ES2426194T3 (es)
HK (1) HK1118836A1 (es)
IL (1) IL189146A0 (es)
WO (1) WO2007044115A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512090A (ja) * 2002-10-31 2006-04-13 ウイスコンシン アラムニ リサーチ ファンデーション ボツリヌス神経毒ｂ受容体およびその使用
JP2009502205A (ja) * 2005-08-02 2009-01-29 プラネット・バイオテクノロジー・インコーポレイテッド 炭疽菌の処置および予防のための改良されたキメラ毒素受容体タンパクおよびキメラ毒素受容体タンパク質
WO2021245580A1 (ko) * 2020-06-04 2021-12-09 주식회사 엠제이셀바이오 Pa63 도메인 4 변이체를 세포외 결합 도메인으로 포함하는 키메라 항원 수용체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
EP0807173B1 (en) * 1994-12-30 2007-08-08 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
US6495128B1 (en) * 1998-11-10 2002-12-17 Human Genome Sciences, Inc. Human chemokine β-7 deletion and substitution proteins
EP1218501A1 (en) * 1999-09-24 2002-07-03 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
GB9926336D0 (en) * 1999-11-05 2000-01-12 Isis Innovation Universal flourescent sensors
ATE442386T1 (de) * 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
AU6176001A (en) * 2000-05-18 2001-11-26 Us Health Immunotoxin fusion proteins and means for expression thereof
MXPA05001953A (es) * 2002-08-20 2005-06-22 Genitrix Llc Composiciones de lecitina y metodos para modular una respuesta inmune a un antigeno.
GB0423974D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa Proteins
JP2009502205A (ja) * 2005-08-02 2009-01-29 プラネット・バイオテクノロジー・インコーポレイテッド 炭疽菌の処置および予防のための改良されたキメラ毒素受容体タンパクおよびキメラ毒素受容体タンパク質

Also Published As

Publication number Publication date
CN101277970B (zh) 2014-05-07
EP1922329B1 (en) 2013-05-29
KR20080052566A (ko) 2008-06-11
HK1118836A1 (en) 2009-02-20
WO2007044115A3 (en) 2007-11-29
KR101435420B1 (ko) 2014-09-25
JP2014155484A (ja) 2014-08-28
AU2006299933A1 (en) 2007-04-19
IL189146A0 (en) 2008-08-07
WO2007044115A2 (en) 2007-04-19
CA2617877A1 (en) 2007-04-19
CN101277970A (zh) 2008-10-01
JP2009502205A (ja) 2009-01-29
EP1922329A2 (en) 2008-05-21

Similar Documents

Publication Publication Date Title
NO20063026L (no) Antistoffer
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
PE20120429A1 (es) Proteinas de enlace de miostatina
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
CY1119412T1 (el) Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
EA200700136A1 (ru) Анти-cd154-антитела
BRPI0514115A (pt) terapia de combinação empregando-se proteìnas de fusão de transferrina compreendendo glp-1
CY1117756T1 (el) Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης
PE20090711A1 (es) Region constante de anticuerpo mutante
ATE545657T1 (de) Tgf-beta antikörper
PE20081392A1 (es) Moleculas de enlace de lingo
ES2677246T3 (es) Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
DE602007009373D1 (de) Kombination aus einem anti-edb-fibronectin-domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
GB0514779D0 (en) Biological products
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
PE20131141A1 (es) Anticuerpo monoclonal
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
BRPI0314814C1 (pt) anticorpo compreendendo uma variante de fc
HK1109636A1 (en) Human antibodies and proteins